Valneva SE Engages with Investors
Valneva SE (NASDAQ: VALN, PARIS: VLA) is set to enhance its visibility and strategic partnerships by engaging in key investor meetings at prominent healthcare conferences. The company's management team will discuss crucial developments in its pipeline, particularly focusing on its Lyme disease vaccine candidate, VLA15.
Upcoming Investor Conferences
Guggenheim Healthcare Innovation Conference
On November 10, Valneva will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference. The event will feature a fireside chat at 10:30 AM EST, where representatives will discuss the latest advancements and value drivers of the company.
Stifel 2025 Healthcare Conference
Following this, on November 11, the management will present at the Stifel 2025 Healthcare Conference at 9:20 AM EST. The fireside chat format allows for deep, insightful conversations about the company’s strategy and pipeline milestones.
Jefferies London Healthcare Conference
Valneva will also be featured in the Jefferies London Healthcare Conference on November 19 at 2:00 PM GMT. With a focus on investor relations, this conference offers another venue for the company to engage with global investors.
Key Focus: Lyme Disease Vaccine
A central topic during these discussions will be Valneva's VLA15, the only Lyme disease vaccine candidate currently in advanced clinical development. Partnered with Pfizer, this vaccine aims to address significant unmet medical needs. If the Phase 3 trial outcomes are favorable, Pfizer plans to submit applications for market authorization in both the U.S. and European markets as early as 2026, with a potential launch in 2027.
Investor Engagement Process
Institutions wishing to meet Valneva's management during these conferences can request meetings through their respective bank representatives. This engagement signifies Valneva's commitment to transparency and open communication with its investors.
About Valneva SE
Valneva SE is a leading specialty vaccine company dedicated to developing and commercializing vaccines geared toward infectious diseases. The company is unique in its approach, utilizing extensive expertise across various vaccine modalities to create innovative solutions for public health.
With a robust pipeline, Valneva has successfully advanced several vaccines from research and development to market readiness. Their current portfolio includes three proprietary travel vaccines, with ongoing efforts to introduce additional candidates targeting serious health threats, such as Lyme disease and Shigella.
Valneva's Commitment to Public Health
Valneva's growth is supported by revenues from its commercial operations, which fuel the continued development of its vaccine pipeline. The company is determined to streamline access to effective vaccines for a variety of infectious diseases, which remains a critical focus in today's health landscape.
Investor and Media Contacts
For inquiries, investors can reach out to Laetitia Bachelot-Fontaine, VP of Global Communications and European Investor Relations at +33 (0)6 4516 7099, or email laetitia.bachelotfontaine@valneva.com. Joshua Drumm, Ph.D., VP of Global Investor Relations, is also available at +001 917 815 4520 or joshua.drumm@valneva.com.
Frequently Asked Questions
What is the focus of Valneva's upcoming presentations?
Valneva will focus on its Lyme disease vaccine candidate, VLA15, and upcoming investor engagements.
When is the Guggenheim Healthcare Innovation Conference?
The conference is set for November 10, starting at 10:30 AM EST.
How can investors meet with Valneva's management?
Investors should submit requests through their representatives at respective banks for one-on-one meetings.
What vaccines are currently marketed by Valneva?
Valneva currently markets three proprietary travel vaccines and is developing other candidates targeting significant health threats.
What future milestones should investors look for?
Key milestones include Phase 3 trial results for VLA15, with market authorization applications expected in 2026.
